Scholarlink

<p>Anti-Ro/SSA and La/SSB antibodies can cross the placenta, affecting fetal cardiac development and leading to congenital heart block (CHB), a condition characterized by rapid progression, high mortality, and poor prognosis, emphasizing the importance of timely diagnosis and treatment. Fetal echocardiography is a critical diagnostic tool for CHB. With advancements in medicine and shifting health perspectives, the incidence, diagnostic approaches, and treatment methods for CHB are evolving. This review examines the impact of maternal antibodies on offspring, including their pathogenic mechanisms and other influencing factors such as antibody levels and maternal conditions. It also evaluates the application of fetal echocardiography in diagnosing CHB, covering techniques like M-mode, tissue Doppler, and spectral Doppler, and investigates antibody-associated CHB incidence. In addition, the review discusses management strategies for anti-Ro/SSA and anti-La/SSB positive pregnancies, including fetal in-utero treatment, preventive therapy for mothers, and other pharmacologic interventions. The findings highlight that antibody-related CHB is multifactorial, necessitating comprehensive consideration of influencing factors, prenatal counseling, and preventive medication management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of maternal anti-Ro/La antibodies on fetal atrioventricular conduction evaluated with echocardiography: a state-of-the-art review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月11日

查看全文
  • Ya-Ting Fan,
  • You-Bin Deng

摘要

Anti-Ro/SSA and La/SSB antibodies can cross the placenta, affecting fetal cardiac development and leading to congenital heart block (CHB), a condition characterized by rapid progression, high mortality, and poor prognosis, emphasizing the importance of timely diagnosis and treatment. Fetal echocardiography is a critical diagnostic tool for CHB. With advancements in medicine and shifting health perspectives, the incidence, diagnostic approaches, and treatment methods for CHB are evolving. This review examines the impact of maternal antibodies on offspring, including their pathogenic mechanisms and other influencing factors such as antibody levels and maternal conditions. It also evaluates the application of fetal echocardiography in diagnosing CHB, covering techniques like M-mode, tissue Doppler, and spectral Doppler, and investigates antibody-associated CHB incidence. In addition, the review discusses management strategies for anti-Ro/SSA and anti-La/SSB positive pregnancies, including fetal in-utero treatment, preventive therapy for mothers, and other pharmacologic interventions. The findings highlight that antibody-related CHB is multifactorial, necessitating comprehensive consideration of influencing factors, prenatal counseling, and preventive medication management.